These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 31422033)

  • 1. Simple blood fibrosis tests reduce unnecessary referrals for specialized evaluations of liver fibrosis in NAFLD and ALD patients.
    Broussier T; Lannes A; Zuberbuhler F; Oberti F; Fouchard I; Hunault G; Cales P; Boursier J
    Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):349-355. PubMed ID: 31422033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD.
    Boursier J; Guillaume M; Leroy V; Irlès M; Roux M; Lannes A; Foucher J; Zuberbuhler F; Delabaudière C; Barthelon J; Michalak S; Hiriart JB; Peron JM; Gerster T; Le Bail B; Riou J; Hunault G; Merrouche W; Oberti F; Pelade L; Fouchard I; Bureau C; Calès P; de Ledinghen V
    J Hepatol; 2019 Aug; 71(2):389-396. PubMed ID: 31102719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A stepwise algorithm using an at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis.
    Boursier J; de Ledinghen V; Leroy V; Anty R; Francque S; Salmon D; Lannes A; Bertrais S; Oberti F; Fouchard-Hubert I; Calès P
    J Hepatol; 2017 Jun; 66(6):1158-1165. PubMed ID: 28088581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events.
    Boursier J; Hagström H; Ekstedt M; Moreau C; Bonacci M; Cure S; Ampuero J; Nasr P; Tallab L; Canivet CM; Kechagias S; Sánchez Y; Dincuff E; Lucena A; Roux M; Riou J; Trylesinski A; Romero-Gomez M
    J Hepatol; 2022 May; 76(5):1013-1020. PubMed ID: 35063601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of the combined FibroMeter vibration-controlled transient elastography algorithm in Chinese patients with non-alcoholic fatty liver disease.
    Loong TC; Wei JL; Leung JC; Wong GL; Shu SS; Chim AM; Chan AW; Choi PC; Tse YK; Chan HL; Wong VW
    J Gastroenterol Hepatol; 2017 Jul; 32(7):1363-1369. PubMed ID: 27936280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population.
    Sumida Y; Yoneda M; Hyogo H; Itoh Y; Ono M; Fujii H; Eguchi Y; Suzuki Y; Aoki N; Kanemasa K; Fujita K; Chayama K; Saibara T; Kawada N; Fujimoto K; Kohgo Y; Yoshikawa T; Okanoue T;
    BMC Gastroenterol; 2012 Jan; 12():2. PubMed ID: 22221544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct comparison of the specialised blood fibrosis tests FibroMeter
    Guillaume M; Moal V; Delabaudiere C; Zuberbuhler F; Robic MA; Lannes A; Metivier S; Oberti F; Gourdy P; Fouchard-Hubert I; Selves J; Michalak S; Peron JM; Cales P; Bureau C; Boursier J
    Aliment Pharmacol Ther; 2019 Dec; 50(11-12):1214-1222. PubMed ID: 31617224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distribution of liver stiffness in non-alcoholic fatty liver disease with higher fibrosis-4 index than low cut-off index.
    Tomeno W; Imajo K; Kuwada Y; Ogawa Y; Kikuchi M; Honda Y; Kato T; Kessoku T; Kirikoshi H; Yoneda M; Kitahora T; Saito S; Ozawa Y; Nakajima A
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1411-1416. PubMed ID: 30506860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
    Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Easy Liver Fibrosis Test (eLIFT) for predicting advanced liver fibrosis in patients with chronic hepatitis B.
    Wang J; Chen Z; Yan X; Yang Y; Liu Y; Chen Y; Jia B; Xia J; Xiong Y; Zhang Z; Ding W; Huang R; Wu C
    Discov Med; 2019 Sep; 28(153):149-158. PubMed ID: 31926586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD: a multi-center study.
    Ishiba H; Sumida Y; Tanaka S; Yoneda M; Hyogo H; Ono M; Fujii H; Eguchi Y; Suzuki Y; Yoneda M; Takahashi H; Nakahara T; Seko Y; Mori K; Kanemasa K; Shimada K; Imai S; Imajo K; Kawaguchi T; Nakajima A; Chayama K; Saibara T; Shima T; Fujimoto K; Okanoue T; Itoh Y;
    J Gastroenterol; 2018 Nov; 53(11):1216-1224. PubMed ID: 29744597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic value of alcoholic liver disease (ALD)/nonalcoholic fatty liver disease (NAFLD) index combined with γ-glutamyl transferase in differentiating ALD and NAFLD.
    Wang J; Li P; Jiang Z; Yang Q; Mi Y; Liu Y; Shi R; Zhou Y; Wang J; Lu W; Li S; Liu D
    Korean J Intern Med; 2016 May; 31(3):479-87. PubMed ID: 27025268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease.
    Srivastava A; Gailer R; Tanwar S; Trembling P; Parkes J; Rodger A; Suri D; Thorburn D; Sennett K; Morgan S; Tsochatzis EA; Rosenberg W
    J Hepatol; 2019 Aug; 71(2):371-378. PubMed ID: 30965069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of eLIFT for Non-invasive Assessment of Liver fibrosis and Cirrhosis in Patients with Chronic Hepatitis B Virus Infection.
    Li Q; Lu C; Li W; Huang Y; Chen L
    Sci Rep; 2017 Jul; 7(1):5429. PubMed ID: 28710435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance of non-invasive models of fibrosis in predicting mild to moderate fibrosis in patients with non-alcoholic fatty liver disease.
    Siddiqui MS; Patidar KR; Boyett S; Luketic VA; Puri P; Sanyal AJ
    Liver Int; 2016 Apr; 36(4):572-9. PubMed ID: 26713759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease.
    Boursier J; Vergniol J; Guillet A; Hiriart JB; Lannes A; Le Bail B; Michalak S; Chermak F; Bertrais S; Foucher J; Oberti F; Charbonnier M; Fouchard-Hubert I; Rousselet MC; Calès P; de Lédinghen V
    J Hepatol; 2016 Sep; 65(3):570-8. PubMed ID: 27151181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is there scope to improve the selection of patients with alcohol-related liver disease for referral to secondary care? A retrospective analysis of primary care referrals to a UK liver centre, incorporating simple blood tests.
    Rhodes FA; Cococcia S; Patel P; Panovska-Griffiths J; Tanwar S; Westbrook RH; Rodger A; Rosenberg W
    BMJ Open; 2021 Jun; 11(6):e047786. PubMed ID: 34088709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease.
    Shah AG; Lydecker A; Murray K; Tetri BN; Contos MJ; Sanyal AJ;
    Clin Gastroenterol Hepatol; 2009 Oct; 7(10):1104-12. PubMed ID: 19523535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can FIB4 and NAFLD fibrosis scores help endocrinologists refer patients with non-alcoholic fat liver disease to a hepatologist?
    Nones RB; Ivantes CP; Pedroso MLA
    Arch Endocrinol Metab; 2017; 61(3):276-281. PubMed ID: 28225987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Underappreciation of non-alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis.
    Patel PJ; Banh X; Horsfall LU; Hayward KL; Hossain F; Johnson T; Stuart KA; Brown NN; Saad N; Clouston A; Irvine KM; Russell AW; Valery PC; Williams S; Powell EE
    Intern Med J; 2018 Feb; 48(2):144-151. PubMed ID: 29083080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.